Revalesio’s RNS60 program signals renewed momentum in adjunctive stroke therapeutics
Revalesio presents new RNS60 stroke data showing reduced brain tissue loss and shorter hospital stays. Discover what this could mean for stroke drug development.
Pharma & Biotech